Activity Dates: 06/01/2018 - 04/23/2021
This course is designed for pharmacists and/or other healthcare professionals involved in the medication management of individuals living with psychiatric, neurologic and/or substance use disorders.
Over 5 million people in the United States are living with chronic hepatitis C viral (HCV) infection. Psychiatric illnesses are considered a barrier to achieving sustained virological response (SVR) in patients with HCV but early detection and treatment of depression can improve antiviral adherence. Depressive disorder is a commonly existing comorbidity of HCV, with an estimated prevalence of 14%. Insomnia is associated with specific direct-acting antivirals (DAAs), requiring treatment for some during the 12-24 weeks of treatment and post-treatment surveillance. Psychiatric pharmacists can help improve adherence with antiviral medications by concomitantly managing psychiatric symptoms and monitoring symptom response. In addition to performing baseline psychiatric evaluations and managing interferon-induced psychiatric symptoms, psychiatric pharmacists should provide patient education on HCV and the antiviral medications, and manage drug-drug interactions prior to initiating DAAs. This session will provide training enabling psychiatric pharmacists to perform the basic duties of a clinical hepatic pharmacist, while influencing psychiatric care for patients infected with HCV who require antiviral treatment but develop psychiatric adverse drug reactions.
You will proceed through the following steps to satisfactorily complete this course:
Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Susie H. Park, PharmD, BCPP, FCSHP
View biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of application-based continuing education credit from CPNP approved programming.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2018 CPNP Recertification Editorial Board Disclosures
Mary C. Borovicka, PharmD, BCPP, BCPS |
|
Jessica L. Brennan, PharmD, BCPP Psychiatric Clinical Pharmacy Specialist Cleveland Clinic Marymount Hospital Garfield Heights, OH No Relevant Financial Relationships to Disclose |
|
Beth DeJongh, PharmD, BCPP, BCPS Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
Sara E. Dugan, PharmD, BCPP, BCPS |
|
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA Employment: San Francisco Department of Public Health, Psychiatric Clinical Pharmacist |
|
Rebecca Graham, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health Corporal Michael J. Crescenz VA Medical Center in Philadelphia Philadelphia, PA No Relevant Financial Relationships to Disclose |
|
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
Rex S. Lott, PharmD, BCPP |
|
Monica Mathys, PharmD, BCPP Associate Professor Texas Tech Health Sciences Dallas, TX No Relevant Financial Relationships to Disclose |
Sarah T. Melton, PharmD, BCACP, BCCP |
Thea R. Moore, PharmD, BCPP |
Sandra Mullen, PharmD, BCPP |
Stephanie Nichols, PharmD, BCPP, BCPS |
|
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
|
Megan M. Sarashinsky, PharmD, BCPP Clinical Pharmacy Specialist CJW Medical Center Richmond, VA No Relevant Financial Relationships to Disclose |
|
Michele D. Thomas, PharmD, BCPP Assistant Director of Pharmacy, PI Springfield Hospital Center Sykesville, MD No Relevant Financial Relationships to Disclose |
|
Robin C. Wackernah, PharmD, BCPP Senior Clinical Pharmacist Craig Hospital Englewood, CO No Relevant Financial Relationships to Disclose |
Daina Wells, PharmD, BCPP, BCPS |
|
Niccole M. Winistoerfer, PharmD, BCPP, BCPS Clinical Pharmacist Shawnee Mission Medical Center Shawnee Mission, KS No Relevant Financial Relationships to Disclose |
|
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices. Please indicate drugs and / or devices here: citalopram, diphenhydramine, hydroxyzine, mirtazapine, paroxetine, sertraline, trazodone.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.